- Published on
Medicine – Thrombocytosis
Thrombocytosis is a haematological condition characterised by an elevated platelet count, generally defined as greater than 450 × 10⁹/L.
Thrombocytosis may arise from a primary bone marrow disorder or occur as a secondary (reactive) response to another condition.
The two major categories are primary (clonal) thrombocytosis, particularly essential thrombocythaemia, and secondary (reactive) thrombocytosis, caused by infection, inflammation, splenectomy, malignancy, bleeding, iron deficiency anaemia, trauma and other conditions.
1. Classification of Thrombocytosis
2. Primary Thrombocytosis – Essential Thrombocythaemia
Essential thrombocythaemia (ET), sometimes called essential thrombocytosis, is a chronic myeloproliferative neoplasm characterised by sustained elevation of the platelet count due to clonal proliferation of megakaryocytes in the bone marrow.
A. Pathophysiology
ET is commonly associated with acquired driver mutations affecting pathways responsible for megakaryocyte proliferation and platelet production.
| Mutation | Approximate Frequency |
|---|---|
| JAK2 V617F | 50–60% |
| CALR | 20–30% |
| MPL | 3–5% |
| Triple-negative | Approximately 10% |
These mutations activate signalling pathways involved in megakaryocyte proliferation and platelet production.
B. Clinical Features
Many patients are asymptomatic and diagnosed incidentally following a routine full blood count.
Possible Manifestations
- Headache and dizziness.
- Visual disturbances.
- Erythromelalgia: burning pain, warmth and redness of the hands or feet.
- Arterial thrombosis, including stroke or myocardial infarction.
- Venous thrombosis, including deep vein thrombosis or unusual-site thrombosis.
- Bleeding, particularly with extreme thrombocytosis.
- Mild splenomegaly in some patients.
C. Important Complications
Thrombosis
Thrombosis is a major complication of ET, although individual risk varies according to factors such as age, previous thrombosis and JAK2 mutation status.
Bleeding
Bleeding may occur in extreme thrombocytosis because of acquired von Willebrand syndrome, particularly when the platelet count exceeds approximately 1,000 × 10⁹/L.
Disease Progression
A small proportion of patients may progress to myelofibrosis or acute myeloid leukaemia.
3. Secondary (Reactive) Thrombocytosis
Reactive thrombocytosis occurs when platelet production increases in response to another disease or physiological stimulus.
It is generally more common than primary thrombocytosis.
A. Infection and Inflammatory Disorders
Inflammation stimulates cytokine production, particularly interleukin-6 (IL-6), which promotes thrombopoietin-mediated platelet production.
Common Causes
- Acute bacterial infections.
- Chronic infections, including tuberculosis.
- Rheumatoid arthritis.
- Inflammatory bowel disease.
- Other chronic inflammatory conditions.
Platelet counts often return towards normal after the underlying inflammatory condition resolves.
B. Postsplenectomy or Hyposplenism
The spleen normally sequesters and removes circulating platelets.
After splenectomy, platelet counts may increase because splenic sequestration is reduced.
Thrombocytosis may also occur in functional hyposplenism, including sickle cell disease.
C. Malignancy
Certain malignancies cause reactive thrombocytosis through inflammatory cytokines and tumour-associated stimulation of platelet production.
Examples
- Lung carcinoma.
- Colorectal carcinoma.
- Ovarian carcinoma.
- Other solid tumours.
Persistent unexplained thrombocytosis may warrant investigation for an underlying malignancy, guided by age, symptoms, examination and clinical risk factors.
D. Bleeding
Acute or chronic blood loss may stimulate increased platelet production during marrow recovery.
Chronic bleeding may also cause iron deficiency anaemia, which is itself associated with thrombocytosis.
E. Iron Deficiency Anaemia (IDA)
Iron deficiency anaemia is an important cause of reactive thrombocytosis.
Typical Findings
- Microcytosis.
- Hypochromia.
- Reduced ferritin, unless confounded by inflammation.
- Elevated platelet count in some patients.
The platelet count commonly improves following effective iron replacement.
F. Trauma
Major trauma and tissue injury can trigger an inflammatory response and increased platelet production.
Reactive thrombocytosis may also occur following surgery or during recovery from significant physiological stress.
G. Thrombosis
Thrombocytosis may occur in association with acute thrombotic events because of inflammation or tissue injury.
However, thrombosis may also be a consequence of primary thrombocytosis, especially essential thrombocythaemia.
The relationship should therefore be interpreted in the clinical context rather than assuming thrombosis is always the cause of an elevated platelet count.
4. Summary of Causes
| Primary Thrombocytosis | Secondary Thrombocytosis |
|---|---|
| Essential thrombocythaemia | Infection |
| Other myeloproliferative neoplasms | Inflammatory disorders |
| Polycythaemia vera | Postsplenectomy |
| Prefibrotic primary myelofibrosis | Hyposplenism |
| Chronic myeloid leukaemia | Malignancy |
| — | Bleeding |
| — | Iron deficiency anaemia |
| — | Trauma or surgery |
| — | Associated acute thrombosis |
5. Clinical Features
Thrombocytosis itself may be asymptomatic.
Symptoms and signs depend on whether the condition is primary or reactive and whether complications occur.
| Clinical Feature | Possible Significance |
|---|---|
| Headache, dizziness | Microvascular symptoms, particularly in ET |
| Erythromelalgia | Suggests a myeloproliferative neoplasm |
| Arterial or venous thrombosis | Possible ET complication |
| Unusual bleeding | Consider acquired von Willebrand syndrome |
| Fever | Infection or inflammation |
| Weight loss, night sweats | Possible malignancy or myeloproliferative disease |
| Splenomegaly | May suggest a myeloproliferative neoplasm |
| Microcytic anaemia | Consider iron deficiency |
| Howell–Jolly bodies | Hyposplenism |
6. Investigations
A. Full Blood Count
The full blood count confirms thrombocytosis and assesses the other blood cell lines.
- Elevated haemoglobin or haematocrit: Consider polycythaemia vera.
- Leukocytosis: Infection, inflammation or a myeloproliferative neoplasm.
- Microcytic anaemia: Iron deficiency.
- Persistent isolated thrombocytosis: Consider ET after excluding reactive causes.
B. Peripheral Blood Film
The peripheral blood film helps confirm a genuinely elevated platelet count and assess morphology.
- Increased platelets.
- Large or giant platelets in some myeloproliferative neoplasms.
- Microcytic hypochromic red cells in iron deficiency.
- Howell–Jolly bodies in hyposplenism.
- Other abnormal cell features suggesting marrow disease.
C. Iron Studies
Serum ferritin and transferrin saturation help identify iron deficiency.
D. Inflammatory Markers
CRP and ESR may be elevated in infection or inflammatory disorders.
E. Molecular Testing
When a myeloproliferative neoplasm is suspected, investigations may include:
- JAK2 V617F mutation.
- CALR mutation.
- MPL mutation.
- BCR::ABL1 testing when chronic myeloid leukaemia needs exclusion.
F. Bone Marrow Examination
Bone marrow biopsy may be required to distinguish ET from prefibrotic myelofibrosis and other myeloid neoplasms.
ET typically shows increased numbers of enlarged, mature megakaryocytes with characteristic nuclear morphology.
7. Diagnostic Approach
8. Management
A. Reactive Thrombocytosis
Treatment focuses on the underlying cause.
| Cause | Management |
|---|---|
| Infection | Appropriate antimicrobial treatment when indicated |
| Inflammatory disorder | Control the underlying inflammation |
| Iron deficiency anaemia | Iron replacement and investigation of the cause |
| Malignancy | Treatment of the underlying cancer |
| Postsplenectomy | Monitoring and individualised thrombosis-risk assessment |
| Bleeding | Identify and control the source |
| Trauma | Supportive care and treatment of associated injuries |
Routine antiplatelet treatment is generally not indicated solely for reactive thrombocytosis.
B. Essential Thrombocythaemia
Treatment is guided by thrombosis risk, bleeding risk, age, mutation status and clinical history.
Treatment Options
- Observation in selected very-low-risk patients.
- Low-dose aspirin when appropriate.
- Cytoreductive therapy, such as hydroxycarbamide or pegylated interferon alfa, for selected patients.
- Management of cardiovascular risk factors.
Aspirin requires caution in patients with significant bleeding or acquired von Willebrand syndrome. Extreme thrombocytosis should prompt assessment of bleeding risk before antiplatelet treatment.
9. Essential Thrombocythaemia vs Reactive Thrombocytosis
| Feature | Essential Thrombocythaemia | Reactive Thrombocytosis |
|---|---|---|
| Nature | Clonal marrow disorder | Response to another condition |
| Platelet count | Persistently elevated, sometimes markedly | Variable, occasionally markedly elevated |
| JAK2/CALR/MPL | May be present | Usually absent |
| Thrombosis risk | Increased, depending on risk factors | Usually driven by underlying condition |
| Splenomegaly | May occur | Depends on cause |
| Iron deficiency | May coexist | Common cause |
| Treatment | Risk-adapted antiplatelet or cytoreductive therapy | Treat underlying cause |
10. High-Yield Examination Summary
| Condition | Characteristic Association |
|---|---|
| Essential thrombocythaemia | Persistent thrombocytosis, JAK2/CALR/MPL mutations |
| Infection | Reactive cytokine-mediated platelet production |
| Inflammatory disorders | IL-6 and thrombopoietin stimulation |
| Postsplenectomy | Reduced splenic sequestration |
| Hyposplenism | Howell–Jolly bodies may be present |
| Malignancy | Tumour-associated inflammatory response |
| Bleeding | Reactive marrow response |
| Iron deficiency anaemia | Microcytosis with possible thrombocytosis |
| Trauma | Tissue injury and inflammation |
| Thrombosis | May be associated with reactive changes or be an ET complication |
11. Key Examination Pearls
- Thrombocytosis is generally defined as a platelet count above 450 × 10⁹/L.
- Essential thrombocythaemia is a chronic myeloproliferative neoplasm.
- JAK2, CALR and MPL mutations are associated with essential thrombocythaemia.
- Reactive thrombocytosis is more common than primary thrombocytosis.
- Infection and inflammation are important reactive causes.
- Iron deficiency anaemia may produce thrombocytosis despite reduced haemoglobin.
- Postsplenectomy thrombocytosis results partly from reduced splenic sequestration.
- Persistent unexplained thrombocytosis requires assessment for a myeloproliferative neoplasm.
- Extreme thrombocytosis may cause bleeding due to acquired von Willebrand syndrome.
- Thrombosis is an important complication of essential thrombocythaemia.
Thrombocytosis with microcytic anaemia suggests iron deficiency; thrombocytosis with Howell–Jolly bodies suggests hyposplenism; and persistent unexplained thrombocytosis with a JAK2, CALR or MPL mutation raises suspicion for essential thrombocythaemia or another myeloproliferative neoplasm.
Thrombocytosis accompanied by acute neurological deficits, chest pain, limb ischaemia, suspected venous thromboembolism or significant bleeding requires urgent medical assessment. A markedly elevated platelet count does not exclude bleeding risk.
Kembara Xtra – Medicine Revision Notes